Navigation Links
Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders
Date:11/23/2009

CARLSBAD, Calif., Nov. 23 /PRNewswire-FirstCall/ --

Dear Isis Supporters and Shareholders,

I would like to start by thanking you for your continuing support of Isis. We believe we are at one of the most successful moments in our history. We are truly at the end of the beginning of creating a unique company with a novel drug discovery platform, which we believe addresses many of the issues haunting the pharmaceutical industry.

Our progress is predicated largely upon the success of our flagship drug, mipomersen. Mipomersen continues to perform well and progress toward commercialization. Isis, our investigators and members of the medical community are very encouraged by the results that were presented at the AHA last week. To get a sense of their support of the drug, I would encourage you to listen to the replay of the mipomersen investigator panel presentation that was conducted during AHA last week. I think you will hear not only their enthusiasm for the drug but their hope that mipomersen will provide a new treatment alternative for their patients at very high risk of cardiovascular disease.

We are disappointed with the reaction on Wall Street to what we believe is very positive news. We believe mipomersen will continue to provide results that speak for themselves. Each success brings us closer to getting mipomersen to the market and making the drug available to patients in need.

Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve the productivity of the pharmaceutical industry. With 19 drugs in development, we have one of the largest and most diverse pipelines in our industry. We know that sick people depend on us. We continue to strive for excellence as we create drugs for the future. We also recognize that behind our successes is the support we receive from you. I would like to personally thank you for that.

Sincerely,

Stanley T. Crooke

Isis Chairman and Chief Executive Officer

SOURCE Isis Pharmaceuticals, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
2. Jiangbo Pharmaceuticals to Present at Brean Murray, Carret 2009 China Growth Conference
3. Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results
4. Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008
5. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
6. Vanda Pharmaceuticals Reports Third Quarter 2009 Results
7. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
8. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
9. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
10. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
11. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic Healing, Sedona Arizona's ... brand Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization and wellness ... to the store is just one more way Shamangelic Healing supports people’s quest ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... awareness and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics ... 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... infants born with severe congenital diaphragmatic hernia have better survival rates if surgery ... diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal ...
(Date:4/29/2016)... ... April 29, 2016 , ... World Patent ... Gyrociser, an exercise invention which aids in proper muscle development. , "The Gym ... and Creative Director of World Patent Marketing. "Globalization has threatened the future growth ...
(Date:4/29/2016)... New York, NY (PRWEB) , ... April 29, 2016 , ... New York City based ... surgery . This surgery is a very effective way to treat obstructive sleep apnea. Dr. ... , Orthognathic surgery is a procedure that involves one or both jaw bones. This ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... NEW YORK , April 28, 2016  The ... reached 275 million dollars, according to Kalorama Information and ... includes typing, immunoassays and nucleic acid testing.  The healthcare ... had made progress in developing blood collection stations and ... was made in Kalorama Information,s report, Blood ...
(Date:4/28/2016)... , April 28, 2016   Acsis , a ... that leading IT market research and advisory firm IDC ... the IDC MarketScape: Worldwide Pharmaceutical Track and Trace Software ... report provides an assessment of the capabilities and business ... trace software market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... Schweiz, April 27, 2016 ... CEO Forums in Zürich gab Strekin AG ... Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens von ... bekannt. Für die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe ... angeworben. STR001 wird während der Operation direkt ...
Breaking Medicine Technology: